Zelluna ASA (OSL:ZLNA)
Norway
· Delayed Price · Currency is NOK 23.40
-0.10 (-0.43%)
Apr 29, 2026, 11:03 AM CET
Zelluna ASA Company Description
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway.
It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors.
The company was incorporated in 2016 and is headquartered in Oslo, Norway.
Zelluna ASA
| Country | Norway |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Namir Hassan |
Contact Details
Address: Oslo Cancer Cluster Innovation Park Oslo, 0379 Norway | |
| Phone | 47 41 38 00 80 |
| Website | zelluna.com |
Stock Details
| Ticker Symbol | ZLNA |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0013524942 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Namir Hassan Ph.D. | Chief Executive Officer |
| Geir Christian Melen MSc | Chief Financial Officer |
| Anders Holm Ph.D. | Chief Operating Officer and Head of Business Development |
| Emilie Gauthy Ph.D. | Chief Technology Officer |
| Luise Weigand Ph.D. | Chief Scientific Officer |
| Julia Ino Ph.D. | Head of Project Management |
| Oivind Foss Ph.D. | Head of Clinical Operations |
| Anders Tuv | Co-Founder and Chairman |
| Hans Ivar Robinson | Co-Founder and Non Executive Director |
| Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer |